scholarly journals Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant

Leukemia ◽  
2013 ◽  
Vol 27 (7) ◽  
pp. 1538-1547 ◽  
Author(s):  
G Weber ◽  
U Gerdemann ◽  
I Caruana ◽  
B Savoldo ◽  
N F Hensel ◽  
...  
Keyword(s):  
T Cells ◽  
Stem Cell ◽  
Stem Cell Transplant ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
Graft Versus Leukemia ◽  
Leukemia Antigen ◽  
Graft Versus Leukemia Effect

scholarly journals Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

Blood ◽  
2013 ◽  
Vol 122 (17) ◽  
pp. 2965-2973 ◽  
Author(s):  
Conrad Russell Y. Cruz ◽  
Kenneth P. Micklethwaite ◽  
Barbara Savoldo ◽  
Carlos A. Ramos ◽  
Sharon Lam ◽  
...  
Keyword(s):  
T Cells ◽  
Stem Cell ◽  
B Cell ◽  
Stem Cell Transplant ◽  
Phase 1 ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
B Cell Malignancies ◽  
Phase 1 Study ◽  
Key Points

Key Points Allogeneic CD19-CAR VSTs are well tolerated by patients with relapsed B-cell malignancies post-HSCT. At periods of CD19-CAR VST persistence, these cells demonstrate antitumor activity.

scholarly journals Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8+T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients

2014 ◽  
Vol 58 (9) ◽  
pp. 5602-5605 ◽  
Author(s):  
Estela Giménez ◽  
Carlos Solano ◽  
José Ramón Azanza ◽  
Paula Amat ◽  
David Navarro
Keyword(s):  
T Cells ◽  
Stem Cell ◽  
Stem Cell Transplant ◽  
Response To Therapy ◽  
Cell Transplant ◽  
Allogeneic Stem Cell Transplant ◽  
Transplant Recipients ◽  
Immunological Monitoring ◽  
Trough Plasma ◽  
Cmv Dnaemia

ABSTRACTIt is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8+T cells) appeared to perform better for this purpose.

Sign in / Sign up

Export Citation Format

Share Document